RU95121693A - Производные глицерина, средство для доставки лекарств (dds) и фармацевтическая композиция - Google Patents
Производные глицерина, средство для доставки лекарств (dds) и фармацевтическая композицияInfo
- Publication number
- RU95121693A RU95121693A RU95121693/04A RU95121693A RU95121693A RU 95121693 A RU95121693 A RU 95121693A RU 95121693/04 A RU95121693/04 A RU 95121693/04A RU 95121693 A RU95121693 A RU 95121693A RU 95121693 A RU95121693 A RU 95121693A
- Authority
- RU
- Russia
- Prior art keywords
- dds
- drug delivery
- phospholipid
- carbamoyl
- glycerol
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 7
- 229940079593 drugs Drugs 0.000 title claims 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title 1
- 150000003904 phospholipids Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
- -1 pyrrolidino, piperidino Chemical group 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- 108020004461 Double-Stranded RNA Proteins 0.000 claims 2
- VJYCNPOOFFTSFC-WRBBJXAJSA-N [3-[4-(dimethylamino)butanoyloxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COC(=O)CCCN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC VJYCNPOOFFTSFC-WRBBJXAJSA-N 0.000 claims 2
- NEDUDHHAROJEIW-SXAUZNKPSA-N [4-amino-2-[2-(diethylamino)ethoxy]-3-[(Z)-octadec-9-enoyl]oxy-4-oxobutyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OCCN(CC)CC)C(C(N)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC NEDUDHHAROJEIW-SXAUZNKPSA-N 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000002740 cytidyl group Chemical group 0.000 claims 2
- 150000002314 glycerols Chemical class 0.000 claims 2
- RFYKUQYHODECFI-WRBBJXAJSA-N 2,3-bis[(Z)-octadec-9-enoxy]propyl N-[2-(dimethylamino)ethyl]carbamate Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(COC(=O)NCCN(C)C)OCCCCCCCC\C=C/CCCCCCCC RFYKUQYHODECFI-WRBBJXAJSA-N 0.000 claims 1
- XAGOXVZLVPBXID-SXAUZNKPSA-N 4-[2-(diethylamino)ethoxy]-2,3-bis[(Z)-octadec-9-enoxy]butanamide Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(COCCN(CC)CC)C(C(N)=O)OCCCCCCCC\C=C/CCCCCCCC XAGOXVZLVPBXID-SXAUZNKPSA-N 0.000 claims 1
- CJCNWOQUBWCVMQ-WRBBJXAJSA-N CN(CCOCC(C(OC(CCCCCCC\C=C/CCCCCCCC)=O)C(N)=O)OC(CCCCCCC\C=C/CCCCCCCC)=O)C Chemical compound CN(CCOCC(C(OC(CCCCCCC\C=C/CCCCCCCC)=O)C(N)=O)OC(CCCCCCC\C=C/CCCCCCCC)=O)C CJCNWOQUBWCVMQ-WRBBJXAJSA-N 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 claims 1
Claims (12)
1. Производные глицерина общей формулы I
где R1 и R2 - не одинаковы и каждый представляет ОY или -А(СН2)n-Е;
n представляет целое число от 0 до 4;
Е представляет пирролидино, пиперидино, замещенный или незамещенный пиперазино, морфолино, замещенный или незамещенный гуанидино или
где R3 и R4 - одинаковы или различны и каждый представляет водород, низший С1-C4-алкил, гидроксинизший-С1-C4-алкил или моно- или ди-(низший) алкиламиноалкил-С2-C8;
А представляет следующие значения:
R и Y - одинаковы или различны и каждый представляет насыщенную или ненасыщенную алифатическую углеводородную группу, содержащую 10 - 30 атомов углерода, или насыщенный или ненасыщенный остаток жирной кислоты, содержащий от 10 до 30 атомов углерода, однако при этом исключаются соединения, в которых А представляет указанные ранее а n = 1.
где R1 и R2 - не одинаковы и каждый представляет ОY или -А(СН2)n-Е;
n представляет целое число от 0 до 4;
Е представляет пирролидино, пиперидино, замещенный или незамещенный пиперазино, морфолино, замещенный или незамещенный гуанидино или
где R3 и R4 - одинаковы или различны и каждый представляет водород, низший С1-C4-алкил, гидроксинизший-С1-C4-алкил или моно- или ди-(низший) алкиламиноалкил-С2-C8;
А представляет следующие значения:
R и Y - одинаковы или различны и каждый представляет насыщенную или ненасыщенную алифатическую углеводородную группу, содержащую 10 - 30 атомов углерода, или насыщенный или ненасыщенный остаток жирной кислоты, содержащий от 10 до 30 атомов углерода, однако при этом исключаются соединения, в которых А представляет указанные ранее а n = 1.
3. Соединение по п. 1, отличающееся тем, что его выбирают из группы, состоящей из 3-O-(4-диметиламинобутаноил)- 1,2-O-диолеилглицерина, 3-O-(2-диметиламиноэтил)карбамоил-1,2-O- диолеилглицерина, 3-O-(2-диэтиламиноэтил)карбамоил-1,2-O-диолеилглицерина и 2-O-(2-диэтиламиноэтил)карбамоил-1,3-O-диолеоилглицерина.
4. Средство для доставки лекарства (DDS), отличающееся тем, что содержит соединение общей формулы I и фосфолипид в качестве основных компонентов.
5. Средство для доставки лекарств (DDS) по п. 4, отличающееся тем, что содержит соединение общей формулы I' и фосфолипид в качестве основных компонентов.
6. Средство для доставки лекарств (DDS) по п. 4, отличающееся тем, что содержит соединение, выбранное из группы, состоящей из 3-O-(4- диметиламинобутаноил)-1,2-O-диолеилглицерина, 3-O-(2-диметиламиноэтил)карбамоил-1,2-O-диолеилглицерина, 3-O-(2-диэтиламиноэтил)карбамоил-1,2-O-диолеилглицерина и 2-O-(2-диэтиламиноэтил)карбамоил-1,3-O-диолеоилглицерина и фосфолипид в качестве основных компонентов.
7. Средство для доставки лекарств (DDS) по п. 4, отличающееся тем, что указанный фосфолипид является фосфатидилэтаноламином или фосфатидилхолином.
8. Средство для доставки лекарств (DDS) по п. 5, отличающееся тем, что указанный фосфолипид является фосфатидилэтаноламином или фосфатидилхолином.
9. Средство для доставки лекарств (DDS) по п. 6, отличающееся тем, что указанный фосфолипид является фосфатидилэтаноламином или фосфатидилхолином.
10. Фармацевтическая композиция, отличающаяся тем, что содержит средство, заявленное в любом из пп. 4 - 9, и физиологически активное вещество.
11. Фармацевтическая композиция по п. 10, отличающаяся тем, что указанное физиологически активное вещество является двухнитевой РНК.
12. Фармацевтическая композиция по п. 10, отличающаяся тем, что указанное физиологически активное вещество является двухнитевой РНК, состоящей из сополимера полинозиновой кислоты и цитидиловой кислоты, содержащего одно звено 4-тиоурудиловой кислоты на каждые 20 звеньев цитидиловой кислоты и полное распределение по размерам молекул в интервале около 50 - 10000 оснований.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPHEI-5/054,939 | 1993-02-19 | ||
JP5493993 | 1993-02-19 | ||
PCT/JP1994/000237 WO1994019314A1 (en) | 1993-02-19 | 1994-02-17 | Glycerol derivative, device and pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95121693A true RU95121693A (ru) | 1997-09-27 |
RU2123492C1 RU2123492C1 (ru) | 1998-12-20 |
Family
ID=12984615
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95121696/14A RU2143903C1 (ru) | 1993-02-19 | 1994-02-17 | Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты |
RU95121693A RU2123492C1 (ru) | 1993-02-19 | 1994-02-17 | Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95121696/14A RU2143903C1 (ru) | 1993-02-19 | 1994-02-17 | Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты |
Country Status (11)
Country | Link |
---|---|
US (2) | US6020317A (ru) |
EP (2) | EP0685457B1 (ru) |
JP (1) | JP3189279B2 (ru) |
KR (2) | KR100283601B1 (ru) |
AT (2) | ATE187713T1 (ru) |
AU (2) | AU6044994A (ru) |
CA (2) | CA2156289C (ru) |
DE (2) | DE69424406T2 (ru) |
ES (1) | ES2142934T3 (ru) |
RU (2) | RU2143903C1 (ru) |
WO (2) | WO1994019314A1 (ru) |
Families Citing this family (284)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11508231A (ja) * | 1995-05-26 | 1999-07-21 | ソマティックス セラピー コーポレイション | 安定な脂質/核酸複合体を含む送達ビヒクル |
CA2223179A1 (en) | 1995-06-07 | 1996-12-19 | Bob Dale Brown | Phosphonic acid-based cationic lipids |
JPH11507352A (ja) * | 1995-06-07 | 1999-06-29 | ジンタ・インコーポレイテッド | 新規カルバメート基本カチオン性脂質 |
AU734968B2 (en) * | 1996-07-22 | 2001-06-28 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Vectors for inhibiting HIV and tumor growth |
FR2759367A1 (fr) * | 1997-02-10 | 1998-08-14 | Transgene Sa | Glycerolipides cationiques et complexes de glycerolipides cationiques et de substances actives, notamment pour la transfection de cellules |
FR2759382A1 (fr) * | 1997-02-10 | 1998-08-14 | Transgene Sa | Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
US6716625B1 (en) | 1997-04-16 | 2004-04-06 | Claude Selitrennikoff | Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use |
JP2002510319A (ja) | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法 |
TW524693B (en) * | 1997-10-16 | 2003-03-21 | Nippon Shinyaku Co Ltd | Cancer cell nuclease activator |
MY134896A (en) | 1998-03-24 | 2007-12-31 | Nippon Shinyaku Co Ltd | Therapeutic agent for hepatitis |
US6043390A (en) * | 1998-04-03 | 2000-03-28 | The Regents Of The University Of California | Pentaerythritol lipid derivatives and nucleic-acid complexes |
EP1469009A2 (en) * | 1998-05-21 | 2004-10-20 | Isis Parmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
AU753270B2 (en) * | 1998-05-21 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
KR100644172B1 (ko) * | 1998-05-25 | 2006-11-10 | 니뽄 신야쿠 가부시키가이샤 | 핵산 함유 복합체 제제의 제조 방법 |
DE60021354T2 (de) * | 1999-02-15 | 2006-04-27 | Nippon Shinyaku Co., Ltd. | Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
WO2001042200A1 (en) * | 1999-12-10 | 2001-06-14 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20030176385A1 (en) * | 2000-02-15 | 2003-09-18 | Jingfang Ju | Antisense modulation of protein expression |
US20030134420A1 (en) * | 2000-02-18 | 2003-07-17 | Lollo Charles Peter | Methods and compositions for gene delivery |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US7427394B2 (en) * | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
USRE43612E1 (en) | 2000-10-10 | 2012-08-28 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
AU2002246541A1 (en) * | 2000-11-28 | 2002-08-06 | Promega Corporation | Rna polymers and uses thereof |
GB0106041D0 (en) * | 2001-03-12 | 2001-05-02 | Cancer Res Ventures Ltd | Lipids and liposomes |
CA2790034A1 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
NZ566396A (en) | 2001-10-09 | 2009-07-31 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
WO2003057916A2 (en) | 2002-01-09 | 2003-07-17 | Riken | Cancer profiles |
DE10207177A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
US20060193905A1 (en) * | 2002-05-14 | 2006-08-31 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
EP2330194A3 (en) * | 2002-09-13 | 2011-10-12 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
US7229976B2 (en) | 2002-09-26 | 2007-06-12 | Isis Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
PT1569695E (pt) | 2002-11-13 | 2013-07-16 | Genzyme Corp | Modulação anti-sentido da expressão de apolipoproteína |
WO2004044181A2 (en) | 2002-11-13 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
WO2004071453A2 (en) | 2003-02-13 | 2004-08-26 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of pouchitis |
JP4623426B2 (ja) * | 2003-05-30 | 2011-02-02 | 日本新薬株式会社 | オリゴ核酸担持複合体、当該複合体を含有する医薬組成物 |
JP4505749B2 (ja) * | 2003-05-30 | 2010-07-21 | 日本新薬株式会社 | Bcl−2の発現抑制をするオリゴ二本鎖RNAとそれを含有する医薬組成物 |
US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
WO2005041870A2 (en) * | 2003-10-24 | 2005-05-12 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
WO2005074633A2 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US7947659B2 (en) * | 2004-03-12 | 2011-05-24 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
EP1742958B1 (en) | 2004-03-15 | 2017-05-17 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US8815599B2 (en) * | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US7498315B2 (en) * | 2004-06-01 | 2009-03-03 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
WO2006085987A2 (en) | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
JP5087924B2 (ja) * | 2004-08-26 | 2012-12-05 | 日本新薬株式会社 | ガラクトース誘導体、薬物担体及び医薬組成物 |
US7973084B2 (en) | 2005-04-28 | 2011-07-05 | Postech Academy-Industrial Foundation | Molecular transporters based on alditol or inositol and processes for the preparation thereof |
KR100699279B1 (ko) * | 2005-04-28 | 2007-03-23 | 학교법인 포항공과대학교 | 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법 |
EP1886688A4 (en) | 2005-05-30 | 2013-01-09 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING PREPARATION OF A NUCLEIC ACID-CONTAINING COMPLEX |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
EP1907858A4 (en) * | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
KR100789323B1 (ko) * | 2005-07-20 | 2007-12-28 | 주식회사 엔지켐 | 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체 |
EP2612870A1 (en) | 2005-09-12 | 2013-07-10 | The Regents of the University of Michigan | Recurrent gene fusions in prostate cancer |
US8652467B2 (en) * | 2005-10-14 | 2014-02-18 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2007053577A2 (en) | 2005-10-31 | 2007-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US7723477B2 (en) * | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP1951737A4 (en) * | 2005-11-01 | 2009-07-01 | Alnylam Pharmaceuticals Inc | INHIBITION OF INFLUENZA VIRUS REPLICATION BY RNA INTERFERENCE |
WO2007064857A2 (en) | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
US8229398B2 (en) * | 2006-01-30 | 2012-07-24 | Qualcomm Incorporated | GSM authentication in a CDMA network |
CA2638797A1 (en) * | 2006-03-01 | 2007-09-07 | Nippon Shinyaku Co., Ltd. | Galactose derivative, drug carrier and medicinal composition |
KR101362681B1 (ko) | 2006-03-31 | 2014-02-13 | 알닐람 파마슈티칼스 인코포레이티드 | Eg5 유전자의 발현을 억제하는 조성물 및 억제 방법 |
EP2013222B1 (en) * | 2006-04-28 | 2013-02-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the jc virus |
BRPI0712034A2 (pt) | 2006-05-19 | 2012-01-10 | Alnylam Pharmaceuticals Inc | modulação de rnai de aha e usos terapêuticos do mesmo |
US7888498B2 (en) * | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
EP2032652A4 (en) * | 2006-06-05 | 2011-08-17 | Massachusetts Inst Technology | NETWORKED DEVELOPABLE POLYMERS AND ITS USE |
WO2008011561A2 (en) * | 2006-07-21 | 2008-01-24 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
US20080261216A1 (en) * | 2006-09-08 | 2008-10-23 | The Regents Of The University Of Michigan | HERV Group II Viruses In Lymphoma And Cancer |
WO2008045952A2 (en) * | 2006-10-10 | 2008-04-17 | The Regents Of The University Of Michigan | Photoreceptor precursor cells |
US8048998B2 (en) * | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
WO2008096690A1 (ja) | 2007-02-05 | 2008-08-14 | Nippon Shinyaku Co., Ltd. | ポリエチレングリコール誘導体 |
WO2008109806A2 (en) * | 2007-03-08 | 2008-09-12 | Massachusetts Institute Of Technology | Electrostatic coating of particles for drug delivery |
EP2905336A1 (en) | 2007-03-29 | 2015-08-12 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
KR20100029079A (ko) * | 2007-05-15 | 2010-03-15 | 헬리콘 테라퓨틱스 인코퍼레이티드 | Gpr12의 저해로 인지 질환을 치료하는 방법 |
AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US20090324596A1 (en) * | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
PL3009148T3 (pl) | 2007-07-02 | 2019-03-29 | Oncomed Pharmaceuticals, Inc. | Kompozycje oraz sposoby leczenia i diagnozowania nowotworu |
CA2814246A1 (en) | 2007-07-06 | 2009-01-15 | The Regents Of The University Of Michigan | Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer |
US8865178B2 (en) | 2007-07-17 | 2014-10-21 | University Of Massachusetts | Compositions and methods for wound healing |
US8084057B2 (en) | 2007-07-17 | 2011-12-27 | University Of Massachusetts | Compositions and methods for wound healing |
EP2179292B1 (en) | 2007-08-16 | 2012-11-28 | The Regents of the University of Michigan | Metabolomic profiling of prostate cancer |
JP5049713B2 (ja) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置 |
AU2008335202A1 (en) | 2007-12-10 | 2009-06-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor VII gene |
WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
WO2009100351A2 (en) * | 2008-02-08 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Delivery of rnai constructs to oligodendrocytes |
AU2009221775B2 (en) | 2008-03-05 | 2015-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
WO2009129385A1 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
CA2727428A1 (en) | 2008-06-19 | 2009-12-23 | Nippon Shinyaku Co., Ltd. | Drug carrier |
US8252762B2 (en) | 2008-08-25 | 2012-08-28 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2690175B1 (en) | 2008-09-02 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
EP3109321B1 (en) | 2008-09-25 | 2019-05-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
RU2579897C2 (ru) | 2008-09-26 | 2016-04-10 | Онкомед Фармасьютикалс, Инк. | Агенты, связывающие рецептор "frizzled", и их применение |
CA2742954C (en) | 2008-11-07 | 2018-07-10 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US8846012B2 (en) * | 2008-12-22 | 2014-09-30 | Pola Chemical Industries Inc. | Melanin production inhibitor |
JP2012514475A (ja) | 2009-01-09 | 2012-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌における再現性の遺伝子融合物 |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
AU2010223967B2 (en) | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
EP2756845B1 (en) | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
US20100272824A1 (en) * | 2009-04-16 | 2010-10-28 | The Texas A&M University System | Compositions and methods for preventing and monitoring disease |
WO2010132821A2 (en) | 2009-05-14 | 2010-11-18 | The General Hospital Corporation | Methods and compositions for treating degenerative and ischemic disorders |
WO2010141630A1 (en) | 2009-06-03 | 2010-12-09 | University Of Southern California | Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway |
EP2823810B9 (en) | 2009-07-09 | 2019-10-30 | Novosom Verwaltungs GmbH | Amphoteric liposomes comprising imino lipids |
AP2015008874A0 (en) | 2009-08-14 | 2015-11-30 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
WO2011025540A1 (en) | 2009-08-28 | 2011-03-03 | Bellweather Farms | Chemical induction of lactation |
EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
KR20130043102A (ko) | 2010-04-01 | 2013-04-29 | 온코메드 파마슈티칼스, 인크. | 프리즐드-결합 작용제 및 그의 용도 |
US9125931B2 (en) | 2010-04-06 | 2015-09-08 | Massachusetts Institute Of Technology | Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers |
EP4385568A2 (en) | 2010-04-06 | 2024-06-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
JP6081910B2 (ja) | 2010-06-02 | 2017-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 肝線維症治療用組成物および肝線維症の治療法 |
IL300109A (en) * | 2010-06-03 | 2023-03-01 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the transfer of active substances |
US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
CN110123830A (zh) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法 |
US9127275B2 (en) | 2010-12-10 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
JP6177692B2 (ja) | 2011-02-02 | 2017-08-09 | エクスカリアード・ファーマシューティカルズ,インク | 結合組織増殖因子(ctgf)をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法 |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
KR102481317B1 (ko) | 2011-03-29 | 2022-12-26 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
CN111671918A (zh) | 2011-06-08 | 2020-09-18 | 川斯勒佰尔公司 | Mrna递送的脂质纳米颗粒组合物和方法 |
US20140275211A1 (en) | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
SG10201913683WA (en) | 2011-06-21 | 2020-03-30 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
EP3366312A1 (en) | 2011-06-23 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Serpina 1 sirnas: compositions of matter and methods of treatment |
JP2014526887A (ja) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 造血幹細胞移植の成功率を改善する方法 |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
CA3119789A1 (en) | 2011-10-27 | 2013-05-02 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |
CA2856116A1 (en) | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Therapeutic rna switches compositions and methods of use |
CA3165769A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
WO2014047232A2 (en) | 2012-09-21 | 2014-03-27 | Cornell University | C-rel inhibitors and uses thereof |
AU2013334790A1 (en) | 2012-10-23 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using Wnt pathway-binding agents |
PL2929031T4 (pl) | 2012-12-05 | 2022-06-27 | Alnylam Pharmaceuticals, Inc. | Kompozycje iRNA PCSK9 i sposoby ich zastosowania |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014112280A1 (ja) * | 2013-01-17 | 2014-07-24 | 学校法人日本大学 | 油性組成物及び増粘又はゲル形成剤 |
CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
WO2014184655A1 (en) | 2013-02-07 | 2014-11-20 | Olympic Seafood As | Methods for using crustacean phospholipid-peptide-protein complexes |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
AU2014236305B2 (en) | 2013-03-14 | 2019-01-17 | Ethris Gmbh | CFTR mRNA compositions and related methods and uses |
ES2708561T3 (es) | 2013-03-14 | 2019-04-10 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
KR102605775B1 (ko) | 2013-03-14 | 2023-11-29 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 C5 iRNA 조성물 및 그 이용 방법 |
WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
US10246708B2 (en) | 2013-05-06 | 2019-04-02 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
CN110317810A (zh) | 2013-05-22 | 2019-10-11 | 阿尔尼拉姆医药品有限公司 | Tmprss6 irna组合物及其使用方法 |
KR20220154244A (ko) | 2013-05-22 | 2022-11-21 | 알닐람 파마슈티칼스 인코포레이티드 | SERPINA1 iRNA 조성물 및 이의 사용 방법 |
WO2014210031A1 (en) | 2013-06-25 | 2014-12-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Proteomic biomarkers of sepsis in elderly patients |
CN105793423A (zh) | 2013-10-02 | 2016-07-20 | 阿尔尼拉姆医药品有限公司 | 用于抑制lect2基因表达的组合物和方法 |
JP6613227B2 (ja) | 2013-10-04 | 2019-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Alas1遺伝子の発現を阻害する組成物および方法 |
CN106413811A (zh) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | 精氨基琥珀酸合成酶缺乏症的mrna疗法 |
JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのmRNA療法 |
NZ718817A (en) | 2013-10-22 | 2020-07-31 | Massachusetts Inst Technology | Lipid formulations for delivery of messenger rna |
AU2014362262B2 (en) | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
KR102389968B1 (ko) | 2014-02-11 | 2022-04-25 | 알닐람 파마슈티칼스 인코포레이티드 | 케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법 |
ES2750661T3 (es) | 2014-04-25 | 2020-03-26 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
EA201692370A1 (ru) | 2014-05-22 | 2017-03-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
ES2750686T3 (es) | 2014-05-30 | 2020-03-26 | Translate Bio Inc | Lípidos biodegradables para la administración de ácidos nucleicos |
PE20171238A1 (es) | 2014-06-24 | 2017-08-24 | Shire Human Genetic Therapies | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
WO2016024205A1 (en) | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
EP3188734A4 (en) | 2014-09-02 | 2018-01-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
EP3212794B1 (en) | 2014-10-30 | 2021-04-07 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
AU2015350120B2 (en) | 2014-11-17 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
EP3569711B1 (en) | 2014-12-15 | 2021-02-03 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
JP2018510621A (ja) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法 |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
CN115927335A (zh) | 2015-04-13 | 2023-04-07 | 阿尔尼拉姆医药品有限公司 | 类血管生成素3(ANGPTL3)iRNA组合物及其使用方法 |
BR112017021967A2 (pt) | 2015-05-06 | 2018-07-31 | Alnylam Pharmaceuticals Inc | composições do fator xii (fator hageman) (f12), kallikrein b, plasma (fator fletcher) 1 (klkb1), e kininogen 1 (kng1) irna e métodos de uso dos mesmos |
US9861597B2 (en) | 2015-05-19 | 2018-01-09 | Penn State Research Foundation | Gluconate-based compositions as a neonate anticonvulsant |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
FI3310764T3 (fi) | 2015-06-19 | 2023-07-18 | Massachusetts Inst Technology | Alkenyylillä substituoidut 2,5-piperatsiinidionit ja niiden käyttö koostumuksissa agenssin kuljettamiseksi subjektille tai soluun |
CA3036409C (en) | 2015-09-08 | 2023-07-11 | Erik J. Sontheimer | Dnase h activity of neisseria meningitidis cas9 |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
EP4424828A1 (en) | 2015-12-07 | 2024-09-04 | Genzyme Corporation | Methods and compositions for treating a serpinc1-associated disorder |
WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
US10729690B2 (en) | 2016-01-13 | 2020-08-04 | University Of Massachusetts | Antihelminthic medications for pathogenic nematodes |
US10322171B2 (en) | 2016-02-19 | 2019-06-18 | The Board Of Regents Of The University Of Texas Systems | Vaccine with reduced enhancement of viral infection |
CN109152848B (zh) | 2016-03-15 | 2022-12-09 | 马萨诸塞大学 | 抗-crispr化合物以及使用方法 |
US10213503B2 (en) | 2016-05-19 | 2019-02-26 | The Board Of Trustees Of The University Of Texas System | Attenuated Burkholderia mallei strain which protects against pathogenic Burkholderia infections, vaccine containing and use thereof |
JP2019518028A (ja) | 2016-06-10 | 2019-06-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法 |
US11091795B2 (en) | 2016-07-11 | 2021-08-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for diagnosing and treating arrhythmias |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
SG10201913552UA (en) | 2016-12-16 | 2020-03-30 | Alnylam Pharmaceuticals Inc | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
US11241436B2 (en) | 2017-01-25 | 2022-02-08 | Northwestern University | Autophagy inducers for treatment of CNS conditions |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
WO2018208547A1 (en) | 2017-05-10 | 2018-11-15 | University Of Massachusetts | Bivalent dengue/hepatitis b vaccines |
EP3624824B1 (en) | 2017-05-16 | 2024-07-10 | Translate Bio, Inc. | Codon-optimized mrna encoding cftr for use in treating cystic fibrosis |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
CA3069868A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
US11331319B2 (en) | 2017-09-28 | 2022-05-17 | University Of Massachusetts | Combination treatment for neuropsychiatric disorders |
EP3700965A1 (en) | 2017-10-27 | 2020-09-02 | Massachusetts Institute of Technology | Poly (beta-amino esters) and uses thereof |
US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
WO2019103967A1 (en) | 2017-11-22 | 2019-05-31 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
CA3086343A1 (en) | 2017-12-18 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
JP7381469B2 (ja) | 2018-01-03 | 2023-11-15 | ザ、ペン、ステート、リサーチ、ファウンデーション | 新生児抗痙攣薬としてのグルコースオキシダーゼ組成物 |
JP2021522862A (ja) | 2018-05-11 | 2021-09-02 | アルファ アノマリック エスアエス | 7’−5’−アルファ−アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート |
MX2021000099A (es) * | 2018-06-29 | 2021-03-25 | Basf Se | Sales de esteramina. |
JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス, インコーポレイテッド | Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
EP3837367A1 (en) | 2018-08-16 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
CN118421617A (zh) | 2018-08-24 | 2024-08-02 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
CA3117781A1 (en) | 2018-10-26 | 2020-04-30 | Massachusetts Institute Of Technology | Polymer-lipids and compositions |
JP2022542863A (ja) | 2019-07-24 | 2022-10-07 | ハー・ルンドベック・アクチエゼルスカベット | 抗mGluR5抗体及びその使用 |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
BR112022003860A2 (pt) | 2019-09-03 | 2022-08-16 | Alnylam Pharmaceuticals Inc | Composições e métodos para inibir a expressão do gene lect2 |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
CN114728018B (zh) | 2019-11-01 | 2024-07-19 | 阿尔尼拉姆医药品有限公司 | 亨廷顿(HTT)iRNA药剂组合物及其使用方法 |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
WO2021119226A1 (en) | 2019-12-13 | 2021-06-17 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
BR112022015770A2 (pt) | 2020-02-10 | 2022-10-11 | Alnylam Pharmaceuticals Inc | Composições e métodos para silenciar a expressão de vegf-a |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
WO2021195307A1 (en) | 2020-03-26 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
IL297121A (en) | 2020-04-06 | 2022-12-01 | Alnylam Pharmaceuticals Inc | Compositions and methods for silencing myoc expression |
EP4133079A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
JP2023523993A (ja) | 2020-04-27 | 2023-06-08 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法 |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
WO2022076291A1 (en) | 2020-10-05 | 2022-04-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
AU2021365822A1 (en) | 2020-10-21 | 2023-06-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
WO2022087329A1 (en) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
AU2021393417A1 (en) | 2020-12-01 | 2023-06-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
IL304880A (en) | 2021-02-12 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases |
WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
MX2023011466A (es) | 2021-03-29 | 2024-02-01 | Alnylam Pharmaceuticals Inc | Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas. |
JP2024522068A (ja) | 2021-05-18 | 2024-06-11 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法 |
BR112023025224A2 (pt) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos |
WO2023283246A1 (en) | 2021-07-09 | 2023-01-12 | University Of Massachusetts | Modular prime editor systems for genome engineering |
TW202333748A (zh) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物 |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2023085440A1 (ja) | 2021-11-10 | 2023-05-19 | 公益財団法人東京都医学総合研究所 | 難治性ウイルス感染症の治療剤 |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
CN114907243B (zh) * | 2022-02-28 | 2023-10-27 | 东南大学 | 一种可离子化脂质、其组合物及应用 |
CN116120198B (zh) * | 2022-03-21 | 2024-03-15 | 苏州科锐迈德生物医药科技有限公司 | 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 |
WO2023235501A1 (en) | 2022-06-02 | 2023-12-07 | University Of Massachusetts | High fidelity nucleotide polymerase chimeric prime editor systems |
WO2024025824A2 (en) | 2022-07-25 | 2024-02-01 | University Of Massachusetts | Nucleic acid antisense oligomer readthrough of nonsense codons |
TW202424193A (zh) | 2022-09-15 | 2024-06-16 | 美商艾拉倫製藥股份有限公司 | 第13型17β-羥基類固醇去氫酶(HSD17B13)iRNA組成物及其使用方法 |
CN117820149A (zh) * | 2023-12-29 | 2024-04-05 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS5933222A (ja) * | 1982-08-20 | 1984-02-23 | Mitsui Toatsu Chem Inc | 合成デオキシリボ核酸を有効成分とする抗腫瘍剤 |
JPS60104066A (ja) * | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
JPS61500439A (ja) * | 1983-11-21 | 1986-03-13 | リ−ジエンツ オヴ ザ ユニヴア−シテイ− オヴ ミネソタ | 慢性的非経口ホルモン投与用緩衝化ポリオ−ル−ホルモン混合物 |
JPS61103824A (ja) * | 1984-10-27 | 1986-05-22 | Nippon Kayaku Co Ltd | ポリリボイノシン酸・ポリリボシチヂル酸・ポリ−レ−リジン複合体の注射用製剤の新規調製法 |
US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
GB2175588B (en) * | 1985-04-15 | 1988-08-10 | Toyo Jozo Kk | Nucleoside-phospholipid conjugates |
JP2527346B2 (ja) * | 1987-01-27 | 1996-08-21 | 昭 梶 | 抗ウイルス剤 |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US5030454A (en) * | 1987-10-26 | 1991-07-09 | Alza Corporation | Method for delivering drug in tiny pills in liquid carrier |
US4961932A (en) * | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
US4882147A (en) * | 1987-12-16 | 1989-11-21 | The Research Foundation Of State University Of New York | Novel polynucleotide analogs, methods for inhibiting nucleic acid polymerases and methods for inducing synthesis of interferon |
US5231085A (en) * | 1988-10-31 | 1993-07-27 | Sandoz Ltd. | Compositions and methods for the enhancement of host defense mechanisms |
ES2052066T3 (es) * | 1988-10-31 | 1994-07-01 | Sandoz Nutrition Ltd | Mejoras en o relacionadas con compuestos organicos. |
JPH03240795A (ja) * | 1990-02-15 | 1991-10-28 | Ajinomoto Co Inc | 新規オリゴヌクレオチド誘導体及び抗ウイルス剤への使用 |
JP2604268B2 (ja) * | 1990-04-09 | 1997-04-30 | 富士写真フイルム株式会社 | ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜 |
EP0468520A3 (en) * | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
JPH04210921A (ja) * | 1991-02-08 | 1992-08-03 | Asahi Chem Ind Co Ltd | 新規リン脂質・ヌクレオシド誘導体を有効成分とする抗腫瘍剤 |
-
1994
- 1994-02-17 DE DE69424406T patent/DE69424406T2/de not_active Expired - Fee Related
- 1994-02-17 WO PCT/JP1994/000237 patent/WO1994019314A1/ja active IP Right Grant
- 1994-02-17 KR KR1019950703469A patent/KR100283601B1/ko not_active IP Right Cessation
- 1994-02-17 CA CA002156289A patent/CA2156289C/en not_active Expired - Fee Related
- 1994-02-17 EP EP94907060A patent/EP0685457B1/en not_active Expired - Lifetime
- 1994-02-17 RU RU95121696/14A patent/RU2143903C1/ru not_active IP Right Cessation
- 1994-02-17 WO PCT/JP1994/000238 patent/WO1994018987A1/ja active IP Right Grant
- 1994-02-17 ES ES94907060T patent/ES2142934T3/es not_active Expired - Lifetime
- 1994-02-17 KR KR1019950703470A patent/KR100334858B1/ko not_active IP Right Cessation
- 1994-02-17 AT AT94907060T patent/ATE187713T1/de not_active IP Right Cessation
- 1994-02-17 DE DE69422163T patent/DE69422163T2/de not_active Expired - Lifetime
- 1994-02-17 JP JP51881594A patent/JP3189279B2/ja not_active Expired - Fee Related
- 1994-02-17 EP EP94907061A patent/EP0685234B1/en not_active Expired - Lifetime
- 1994-02-17 AT AT94907061T patent/ATE192657T1/de not_active IP Right Cessation
- 1994-02-17 CA CA002156288A patent/CA2156288C/en not_active Expired - Fee Related
- 1994-02-17 AU AU60449/94A patent/AU6044994A/en not_active Abandoned
- 1994-02-17 RU RU95121693A patent/RU2123492C1/ru not_active IP Right Cessation
- 1994-02-17 US US08/507,518 patent/US6020317A/en not_active Expired - Lifetime
- 1994-02-17 AU AU60450/94A patent/AU6045094A/en not_active Abandoned
- 1994-02-17 US US08/507,269 patent/US5705188A/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95121693A (ru) | Производные глицерина, средство для доставки лекарств (dds) и фармацевтическая композиция | |
RU95121696A (ru) | Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты | |
KR960700997A (ko) | 글리세롤 유도체, 디바이스 및 의약 조성물(glycerol derivative, device and pharmaceutical composition) | |
MX9204627A (es) | Compuestos 1-acilpiperidina, procedimiento para su preparacion y composicion farmaceutica que los comprende. | |
ATE4903T1 (de) | 1-, 6- und 2-substituierte 1-carba-2-penem-3carbons[ure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
DE20121305U1 (de) | Nukleosid-Verbindungen | |
KR950031068A (ko) | 골다공증의 복합 치료 | |
ATE138647T1 (de) | 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung als arzneimittel | |
EP0285706A1 (en) | Medicament for the therapeutic treatment of alopecia | |
ATE147272T1 (de) | Pharmazeutische zubereitungsformen | |
ATE15443T1 (de) | Essbare, pharmazeutische zusammensetzungen und verfahren zur herstellung. | |
FI970634A0 (fi) | Syklosporiinien uudet, suun kautta annettavat, koostumukseltaan yksinkertaiset valmistemuodot, joista biosaatavuus on hyvä, sekä menetelmä niiden valmistamiseksi | |
US4396597A (en) | Process for the preparation of a sterile injectable physiologically acceptable solution of an X-ray contrast agent and solutions of the X-ray contrast agent and a buffer | |
KR890005034A (ko) | 디카복실산-비스(3,5-디카바모일-2,4,6,-트리요오도아닐리드) 및 이를 함유하는 x-선 조영제 | |
RU94044435A (ru) | Производные амида витамина д, способы их получения, фармацевтическая композиция и способ лечения | |
RU2003134629A (ru) | Соединения цефема | |
ATE100464T1 (de) | Peptid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
CA2338854A1 (en) | Nitric esters and nitrate salts of specific drugs | |
KR920003991A (ko) | 비(鼻)투약용 칼시톤인을 함유하는 유제 | |
RU2218334C2 (ru) | Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцин-10-олы и фармацевтическая композиция на их основе | |
KR900001675A (ko) | 기관지확장 작용을 갖는 화합물 | |
KR940014287A (ko) | 아이오드화 벤조일 아세탈 및 케탈 | |
DE69426908D1 (de) | Derivate der Phosphonsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten | |
DE3866198D1 (de) | Pharmazeutische zubereitung fuer die intrarektale verabreichung von calcitonin und daraus hergestellte einzeldosisformen. |